Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Activities of alpha-L-fucosidase (alpha-Fucase), N-acetyl-beta-D-glucosaminidase (beta-GlcNA-case), N-acetyl-beta-D-galactosaminidase (beta-GalNAcase) and alpha-mannosidase (alpha-Manase) in sera of normal adults, patients with hepatocellular carcinoma (HCC), benign liver diseases and non-liver diseases were determined by microquantitative spectrophotometry. The results showed that the activity of the four serum glycosidases in patients with HCC was significantly higher than that in normal adults. When the maximum 95% confidence limit was used as the positive line, the positivities of alpha-Fucase, beta-GlcNAcase, beta-GalNAcase and alpha-Manase for the diagnosis of HCC were 66.80%, 37.29%, 32.20% and 18.64%, respectively. There was a close relationship among the four glycosidases without being related to serum alpha-fetoprotein (AFP). Some patients with benign liver diseases and non-liver diseases also had elevated glycosidase activity. However, the increase in several glycosidase activities was mainly found in HCC patients. Hepatitis patients with increased activities of more than one glycosidase were always accompanied with elevated SGPT or other abnormal liver functions. Therefore, serum glycosidase spectrum is useful for the diagnosis and differential diagnosis of HCC, especially in AFP negative HCC patients.
 ...
PMID:[Value of serum glycosidase spectrum in the diagnosis of hepatocellular carcinoma]. 131 91

Using a sandwich enzyme-linked immunoassay, plasma total cathepsin D concentration was assayed in 40 breast cancer patients and 84 patients with various liver diseases and compared to that of 52 normal subjects. There were no significant variations found in breast cancer patients related to tumor size, node invasiveness or metastases. In normal women, cathepsin D levels were slightly but not significantly increased in the luteal phase and in pregnancy. By contrast, plasma cathepsin D concentration was significantly increased in 70-75% of patients with liver disease (cirrhosis, hepatocarcinoma, hepatitis), but not in those with liver steatosis. Cathepsin D was independent of most of the plasma hepatic function tests and was correlated with alpha-fetoprotein in cirrhosis and with alpha-fucosidase in primary hepatocellular carcinoma. We conclude that plasma cathepsin D is not a useful marker in breast cancer. However, since the cellular level of this protease is associated with risk of metastasis in breast cancer, clinical follow-up will be required to test whether high cathepsin D plasma concentration has any prognostic value in liver cirrhosis and primary hepatocarcinoma.
 ...
PMID:Increased plasma cathepsin D concentration in hepatic carcinoma and cirrhosis but not in breast cancer. 166 31

Using spectrophotometric method, we studied the activities of serum alpha-L-fucosidase, N-acetyl-beta-D-glucosaminidase and alpha-D-mannosidase in 94 patients, of whom 32 had acute hepatitis, 4 subacute fulminant hepatitis, 27 chronic active hepatitis, 22 posthepatitic cirrhosis and 9 hepatocellular carcinoma. In comparison with normal controls, the activities of the three glycosidases in the patients were significantly increased. The degree of the elevation of alpha-L-fucosidase activity correlated to the clinical phases and the course of acute infection of hepatitis B virus (HBV). The levels of glycosidase activities could reflect to a certain degree the pathological variations of the liver. Monitoring the levels of glycosidase activities, especially alpha-L-fucosidase, would be helpful in the diagnosis and medical care of viral hepatitis and hepatocellular carcinoma.
 ...
PMID:Activities of serum enzymes in patients with viral hepatitis B, posthepatitic cirrhosis and hepatocellular carcinoma. 217 63

Serum alpha-L-fucosidase (AFU) was determined in 33 patients with hepatocellular carcinoma (HCC), 4 with secondary metastatic liver cancer, 61 with various liver diseases, 12 with gastrointestinal tumor and 50 healthy controls. The results showed that AFU level was significantly higher in HCC (14.48 +/- 5.77) than that in the controls (3.33 +/- 0.72) and in patient with other diseases (P less than 0.01). Serum AFU level was also increased in fulminant hepatitis (8.96 +/- 3.99), acute hepatitis (8.94 +/- 4.94) and chronic hepatitis (7.27 +/- 2.58), P less than 0.01 or 0.05. There was no significant difference in AFU level between the controls and patients with secondary metastatic liver cancer (6.25 +/- 0.84), cirrhosis (6.30 +/- 3.17), gastrointestinal tumor (4.43 +/- 1.64), liver hemangioma and liver abscess (4.86 +/- 2.22). A level exceeding 10.5u was a useful marker for the diagnosis of HCC with 78.8% sensitivity and 90.0% specificity. The diagnostic positivity was 81.8% in low AFP producing HCC, whereas 93.9% in those with elevated AFP. Our data indicate that serum AFU is a useful tumor marker for HCC, particularly in detection of AFP-low or negative HCC patients.
 ...
PMID:[A preliminary study on serum alpha-L-fucosidase assay in the diagnosis of hepatocellular carcinoma]. 248 Feb 10